%0 Journal Article %1 minucci2006histone %A Minucci, Saverio %A Pelicci, Pier Giuseppe %D 2006 %J Nature Reviews Cancer %K cancer epigenetics medicine methods review %P 38-51 %R 10.1038/nrc1779 %T Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer %U https://www.nature.com/articles/nrc1779 %V 6 %X Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.

@article{minucci2006histone, abstract = {Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.}, added-at = {2017-12-03T17:42:58.000+0100}, author = {Minucci, Saverio and Pelicci, Pier Giuseppe}, biburl = {https://www.bibsonomy.org/bibtex/2eb4caf9605fbf99429ff4998cb39e20d/artheibault}, description = {This article discusses the potential of using HDAC inhibitors to treat cancer. Research has found that HDAC inhibitors tend to suppress cell growth, and trigger apoptosis in higher concentrations. Tumor cells appear to be more vulnerable to these effects than ordinary cells. However, not all HDAC inhibitors function the same, and they can be toxic at higher doses.}, doi = {10.1038/nrc1779}, interhash = {3ced23ee9c566b128f03fa4962813870}, intrahash = {eb4caf9605fbf99429ff4998cb39e20d}, journal = {Nature Reviews Cancer}, keywords = {cancer epigenetics medicine methods review}, month = jan, pages = {38-51}, timestamp = {2017-12-03T17:42:58.000+0100}, title = {Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer}, url = {https://www.nature.com/articles/nrc1779}, volume = 6, year = 2006 }